Impact of neoadjuvant hormonal therapy (HT) on quality of life (QL) of patients treated with interstitial brachitherapy (IB) for localized prostate cancer (LPC)

4744 Background: When IB is planned as definitive treatment for LPC, HT is frequently prescribed to shrink the tumor mass and improve treatment outcomes. IB may produce per se a negative impact on ...